The novel sulfonylhydrazine alkylating agent VNP 40101M may be a feasible treatment for patients with relapsed or refractory leukaemia

By  

Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer

By Shin Sang   Jeung Hei-Cheul   Ahn Joong   Rha Sun   Roh Jae   Park Kyung   Kim Dal-Hyun   Kim Chin   Chung Hyun  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 650-658

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

By Argiris Athanassios   Kut Victoria   Luong Lynn   Avram Michael  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 203-212

Springer Publishing Company

Access to resources Recommend Favorite